P624: phase 1 study of jnj-67856633, a first-in-human highly selective malt1 inhibitor, in relapsed/refractory (r/r) b-cell non-hodgkin lymphoma (b-nhl) and chronic lymphocytic leukemia (cll)
HemaSphere(2023)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined